Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Trading Company
Tel: 86-27-84492310
Tel: 008618986076206
Tel: +86 27 84492310
Tel: WhatsApp +8615927784577
Tel: +8618071739296
Mobile: +8615207100586
Tel: 86-27-84492310
Fax: 86-27-84402310
URL: http://www.vanzpharm.com/en/index.html
Province/state: Hubei
City: JIAYU
Street: FANHU INDUSTRY PARK
MaxCard:
CAS NO.1420477-60-6
cas 1420477-60-6 Acalabrutinib powder
Product Name: | Acalabrutinib |
CAS: | 1420477-60-6 |
MF: | C26H23N7O2 |
MW: | 465.51 |
EINECS: | 814-272-0 |
What is Acalabrutinib
Acalabrutinib (ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 3 nM, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. ACP-196 has improved target specificity over ibrutinib with 323-, 94-, 19- and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR.
Acalabrutinib function
Acalabrutinib, is an experimental anti-cancer drug and a selective Bruton's tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL).